PyramIDH
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 48 patients (estimated)
- Sponsors
- Institut de Recherches Internationales Servier
- Collaborators
- Servier Bio-Innovation LLC
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, Randomization
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2062
- NCT Identifier
- NCT06465953
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.